Zhejiang Beid Pharmaceuticals

Zhejiang Beid Pharmaceuticals is a primary manufacturing and research subsidiary of Betta Pharmaceuticals, a leading Chinese biopharmaceutical company specializing in oncology. The company operates a large-scale, GMP-compliant production base in Hangzhou, which is responsible for the commercial manufacturing of key innovative drugs such as Icotinib (Conmana), China's first self-developed small-molecule targeted anti-cancer medication. Beyond manufacturing, the facility supports the parent company's extensive pipeline of tyrosine kinase inhibitors and other targeted therapies for lung cancer and solid tumors. Zhejiang Beid Pharmaceuticals plays a critical role in ensuring the supply chain stability and quality control for Betta's commercialized portfolio in the Chinese market.